Compound class:
Synthetic organic
Comment: M201-A is a novel ryanodine receptor 2 (RyR2) inhibitor [1]. It was principally designed for the treatment of heart failure.
|
|
No information available. |
Summary of Clinical Use ![]() |
M201-A is a clinical candidate. It is formulated as the hydrochloride salt for in vivo studies. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04609059 | First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation | Phase 2 Interventional | Kitasato University | ||
NCT03055403 | First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects | Phase 1 Interventional | Kitasato University | ||
NCT04464681 | Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects | Phase 1 Interventional | Kitasato University | 1 |